<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04858009</url>
  </required_header>
  <id_info>
    <org_study_id>18-009451</org_study_id>
    <secondary_id>NCI-2021-02990</secondary_id>
    <secondary_id>18-009451</secondary_id>
    <secondary_id>P30CA015083</secondary_id>
    <nct_id>NCT04858009</nct_id>
  </id_info>
  <brief_title>Hyperthermic Intraperitoneal Chemotherapy for the Treatment of Pancreatic Cancer and Peritoneal Metastasis</brief_title>
  <official_title>A Phase II Study of Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for Patients With Pancreatic Cancer and Peritoneal Metastasis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase II trial studies the effects of hyperthermic intraperitoneal chemotherapy (HIPEC)&#xD;
      in treating patients with pancreatic cancer that has spread to the internal abdominal area&#xD;
      (peritoneal metastasis). Chemotherapy drugs, such as mitomycin and cisplatin, work in&#xD;
      different ways to stop the growth of tumor cells, either by killing the cells, by stopping&#xD;
      them from dividing, or by stopping them from spreading. HIPEC involves &quot;heated&quot; chemotherapy&#xD;
      that is placed directly in the abdomen through laparoscopic instruments, instead of through&#xD;
      an intravenous injection. This study may help doctors determine how safe and effective HIPEC&#xD;
      work in treating patient with pancreatic cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVE:&#xD;
&#xD;
      I. To assess short-term morbidity and disease-free survival outcomes for patients with&#xD;
      pancreatic adenocarcinoma with limited low volume peritoneal metastasis or positive&#xD;
      peritoneal cytology undergoing hyperthermic intraperitoneal chemotherapy.&#xD;
&#xD;
      SECONDARY OBJECTIVE:&#xD;
&#xD;
      I. To evaluate the efficacy of a polymerase chain reaction (PCR)-based quantitative cell-free&#xD;
      deoxyribonucleic acid (DNA) KRAS mutation assay in identifying patients at risk of peritoneal&#xD;
      recurrence/progression.&#xD;
&#xD;
      OUTLINE:&#xD;
&#xD;
      Patients undergo HIPEC with mitomycin and cisplatin over 60 minutes in the absence of disease&#xD;
      progression or unacceptable toxicity. Patients may undergo additional HIPEC with mitomycin&#xD;
      and cisplatin up to 5 times.&#xD;
&#xD;
      After completion of study treatment, patients are followed up every 6 months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 15, 2021</start_date>
  <completion_date type="Anticipated">May 31, 2026</completion_date>
  <primary_completion_date type="Anticipated">May 31, 2025</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall survival</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>Will be estimated using the Kaplan-Meier method.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Disease free survival</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>Will be estimated using the Kaplan-Meier method.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Peritoneal-free recurrence</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>Will be estimated using the Kaplan-Meier method.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Morbidity rate</measure>
    <time_frame>Up to 30 days</time_frame>
    <description>Measured using the Clavien Dindo scale in the supplementary files</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Morbidity rate determined by hospital length of stay</measure>
    <time_frame>Up to 30 days</time_frame>
    <description>Measured using the Clavien Dindo scale in the hospital length of stay</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Morbidity rate determined in readmission rate</measure>
    <time_frame>Up to 30 days</time_frame>
    <description>Measured using the Clavien Dindo scale in the readmission rate</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Morbidity rate determined by reoperation rate</measure>
    <time_frame>Up to 30 days</time_frame>
    <description>Measured using the Clavien Dindo scale in the reoperation rate</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mortality rate</measure>
    <time_frame>Up to 30 days</time_frame>
    <description>Measured using the Clavien Dindo scale for 30-day mortality</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Metastatic Pancreatic Carcinoma</condition>
  <condition>Stage IV Pancreatic Cancer AJCC v8</condition>
  <arm_group>
    <arm_group_label>Treatment (HIPEC)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients undergo HIPEC with mitomycin and cisplatin over 60 minutes in the absence of disease progression or unacceptable toxicity. Patients may undergo additional HIPEC with mitomycin and cisplatin up to 5 times.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cisplatin</intervention_name>
    <description>Given via HIPEC</description>
    <arm_group_label>Treatment (HIPEC)</arm_group_label>
    <other_name>Abiplatin</other_name>
    <other_name>Blastolem</other_name>
    <other_name>Briplatin</other_name>
    <other_name>CDDP</other_name>
    <other_name>Cis-diammine-dichloroplatinum</other_name>
    <other_name>Cis-diamminedichloridoplatinum</other_name>
    <other_name>Cis-diamminedichloro Platinum (II)</other_name>
    <other_name>Cis-diamminedichloroplatinum</other_name>
    <other_name>Cis-dichloroammine Platinum (II)</other_name>
    <other_name>Cis-platinous Diamine Dichloride</other_name>
    <other_name>Cis-platinum</other_name>
    <other_name>Cis-platinum II</other_name>
    <other_name>Cis-platinum II Diamine Dichloride</other_name>
    <other_name>Cismaplat</other_name>
    <other_name>Cisplatina</other_name>
    <other_name>Cisplatinum</other_name>
    <other_name>Cisplatyl</other_name>
    <other_name>Citoplatino</other_name>
    <other_name>Citosin</other_name>
    <other_name>Cysplatyna</other_name>
    <other_name>DDP</other_name>
    <other_name>Lederplatin</other_name>
    <other_name>Metaplatin</other_name>
    <other_name>Neoplatin</other_name>
    <other_name>Peyrone''s Chloride</other_name>
    <other_name>Peyrone''s Salt</other_name>
    <other_name>Placis</other_name>
    <other_name>Plastistil</other_name>
    <other_name>Platamine</other_name>
    <other_name>Platiblastin</other_name>
    <other_name>Platiblastin-S</other_name>
    <other_name>Platinex</other_name>
    <other_name>Platinol</other_name>
    <other_name>Platinol- AQ</other_name>
    <other_name>Platinol-AQ</other_name>
    <other_name>Platinol-AQ VHA Plus</other_name>
    <other_name>Platinoxan</other_name>
    <other_name>Platinum</other_name>
    <other_name>Platinum Diamminodichloride</other_name>
    <other_name>Platiran</other_name>
    <other_name>Platistin</other_name>
    <other_name>Platosin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hyperthermic Intraperitoneal Chemotherapy</intervention_name>
    <description>Undergo HIPEC with mitomycin and cisplatin</description>
    <arm_group_label>Treatment (HIPEC)</arm_group_label>
    <other_name>HIPEC</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mitomycin</intervention_name>
    <description>Given via HIPEC</description>
    <arm_group_label>Treatment (HIPEC)</arm_group_label>
    <other_name>Ametycine</other_name>
    <other_name>Jelmyto</other_name>
    <other_name>MITO</other_name>
    <other_name>Mito-C</other_name>
    <other_name>Mito-Medac</other_name>
    <other_name>Mitocin</other_name>
    <other_name>Mitocin-C</other_name>
    <other_name>Mitolem</other_name>
    <other_name>Mitomycin C</other_name>
    <other_name>Mitomycin-C</other_name>
    <other_name>Mitomycin-X</other_name>
    <other_name>Mitomycine C</other_name>
    <other_name>Mitosol</other_name>
    <other_name>Mitozytrex</other_name>
    <other_name>Mutamycin</other_name>
    <other_name>Mutamycine</other_name>
    <other_name>NCI-C04706</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age &gt;= 18 but =&lt; 80&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status =&lt; 2&#xD;
&#xD;
          -  Cytologic or histologic proof of adenocarcinoma of the pancreas&#xD;
&#xD;
          -  Leukocytes &gt;= 3,000/uL&#xD;
&#xD;
          -  Absolute neutrophil count &gt;= 1,500/uL&#xD;
&#xD;
          -  Platelets &gt;= 60,000/Ul&#xD;
&#xD;
          -  Serum creatinine =&lt; 1.5 mg/dL&#xD;
&#xD;
          -  Distant metastatic disease of peritoneum may be visualized on imaging:&#xD;
&#xD;
               -  Positive peritoneal cytology&#xD;
&#xD;
               -  Limited carcinomatosis on diagnostic laparoscopy or laparotomy&#xD;
&#xD;
               -  KRASD assay positive peritoneal washings/cytology&#xD;
&#xD;
          -  Completion of preoperative systemic chemotherapy with biochemical, metabolic, and/or&#xD;
             radiographic response defined as a reduction in the baseline CA 19-9 by &gt; 50% or&#xD;
             radiographic response as defined by Response Evaluation Criteria in Solid Tumors&#xD;
             (RECIST) 1.1 or metabolic response on positron emission tomography (PET)-magnetic&#xD;
             resonance imaging (MRI) defined by PET Response Criteria in Solid Tumors (PERCIST)&#xD;
             criteria&#xD;
&#xD;
          -  Peritoneal Carcinomatosis Index (PCI) =&lt; 7 and surgeons deems high likelihood for a&#xD;
             complete cytoreduction&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Distant metastatic disease not limited to peritoneum:&#xD;
&#xD;
               -  Solid organ metastases (liver, central nervous system, lung)&#xD;
&#xD;
          -  Infections such as pneumonia or wound infections that would preclude protocol therapy&#xD;
&#xD;
          -  Women with a positive urine or serum pregnancy test are excluded from this study;&#xD;
             women of childbearing potential (defined as those who have not undergone a&#xD;
             hysterectomy or who have not been postmenopausal for at least 24 consecutive months)&#xD;
             must agree to refrain from breast feeding and practice adequate contraception as&#xD;
             specified in the informed consent. Adequate contraception consists of oral&#xD;
             contraceptive, implantable contraceptives, injectable contraceptives, a double barrier&#xD;
             method, or abstinence&#xD;
&#xD;
          -  Subjects with unstable angina or New York Heart Association grade II or greater&#xD;
             congestive heart failure&#xD;
&#xD;
          -  Subjects deemed unable to comply with study and/or follow-up procedures&#xD;
&#xD;
          -  Subjects with a known hypersensitivity to protocol systemic chemotherapy that was&#xD;
             life-threatening, required hospitalization or prolongation of existing&#xD;
             hospitalization, or resulted in persistent or significant disability or incapacity&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Travis E Grotz</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic in Rochester</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mayo Clinic in Rochester</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Clinical Trials Referral Office</last_name>
      <phone>855-776-0015</phone>
      <email>mayocliniccancerstudies@mayo.edu</email>
    </contact>
    <investigator>
      <last_name>Travis E. Grotz, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>April 14, 2021</study_first_submitted>
  <study_first_submitted_qc>April 22, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 23, 2021</study_first_posted>
  <last_update_submitted>October 6, 2021</last_update_submitted>
  <last_update_submitted_qc>October 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 7, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pancreatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cisplatin</mesh_term>
    <mesh_term>Mitomycins</mesh_term>
    <mesh_term>Mitomycin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

